Similar articles for PMID: 16061839

Year	Number of Results
1978	1
1980	1
1986	1
1987	1
1988	2
1989	3
1991	2
1992	1
1993	2
1994	1
1995	2
1996	2
1997	5
1998	9
1999	4
2000	9
2001	4
2002	6
2003	11
2004	8
2005	8
2006	6
2007	4
2008	5
2009	8
2010	3
2011	3
2012	9
2013	7
2014	6
2015	14
2016	10
2017	7
2018	7
2019	3
2020	1
2021	3
2024	0

1

Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial.

Kühnert B, Byrne M, Simoni M, Köpcke W, Gerss J, Lemmnitz G, Nieschlag E. Kühnert B, et al. Eur J Endocrinol. 2005 Aug;153(2):317-26. doi: 10.1530/eje.1.01964. Eur J Endocrinol. 2005. PMID: 16061839 Clinical Trial.

2

Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.

Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS. Wang C, et al. J Clin Endocrinol Metab. 2004 May;89(5):2085-98. doi: 10.1210/jc.2003-032006. J Clin Endocrinol Metab. 2004. PMID: 15126525 Clinical Trial.

3

Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.

Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Longstreth J, Berman N. Swerdloff RS, et al. J Clin Endocrinol Metab. 2000 Dec;85(12):4500-10. doi: 10.1210/jcem.85.12.7045. J Clin Endocrinol Metab. 2000. PMID: 11134099 Clinical Trial.

4

[Scrotal testosterone patches: a good addition to therapeutic options for hypogonadal men].

Asscheman H, Gooren LJ. Asscheman H, et al. Ned Tijdschr Geneeskd. 2000 Apr 29;144(18):847-50. Ned Tijdschr Geneeskd. 2000. PMID: 10816775 Clinical Trial. Dutch.

5

Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.

Wang C, Berman N, Longstreth JA, Chuapoco B, Hull L, Steiner B, Faulkner S, Dudley RE, Swerdloff RS. Wang C, et al. J Clin Endocrinol Metab. 2000 Mar;85(3):964-9. doi: 10.1210/jcem.85.3.6437. J Clin Endocrinol Metab. 2000. PMID: 10720024 Clinical Trial.

6

Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.

Arver S, Dobs AS, Meikle AW, Caramelli KE, Rajaram L, Sanders SW, Mazer NA. Arver S, et al. Clin Endocrinol (Oxf). 1997 Dec;47(6):727-37. doi: 10.1046/j.1365-2265.1997.3071113.x. Clin Endocrinol (Oxf). 1997. PMID: 9497881 Clinical Trial.

7

Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years.

Behre HM, von Eckardstein S, Kliesch S, Nieschlag E. Behre HM, et al. Clin Endocrinol (Oxf). 1999 May;50(5):629-35. doi: 10.1046/j.1365-2265.1999.00705.x. Clin Endocrinol (Oxf). 1999. PMID: 10468929

8

Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men.

Mazer N, Bell D, Wu J, Fischer J, Cosgrove M, Eilers B; BS, RN,. Mazer N, et al. J Sex Med. 2005 Mar;2(2):213-26. doi: 10.1111/j.1743-6109.2005.20231.x. J Sex Med. 2005. PMID: 16422889 Clinical Trial.

9

Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.

von Eckardstein S, Nieschlag E. von Eckardstein S, et al. J Androl. 2002 May-Jun;23(3):419-25. J Androl. 2002. PMID: 12002444 Free article. Clinical Trial.

10

Treatment of primary hypogonadism in men by the transdermal administration of testosterone.

Findlay JC, Place V, Snyder PJ. Findlay JC, et al. J Clin Endocrinol Metab. 1989 Feb;68(2):369-73. doi: 10.1210/jcem-68-2-369. J Clin Endocrinol Metab. 1989. PMID: 2493029

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

164 results

Results by year